Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial-Reference-Cited by-同舟云学术

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Published:2019-07 Issue:7 Volume:20 Page:961-971
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Saw Robyn P M,Lo Serigne,Nieweg Omgo E,Shannon Kerwin F,Gonzalez Maria,Guminski Alexander,Lee Jenny H,Lee Hansol,Ferguson Peter M,Rawson Robert V,Wilmott James S,Thompson John F,Kefford Richard F,Ch'ng Sydney,Stretch Jonathan R,Emmett Louise,Kapoor Rony,Rizos Helen,Spillane Andrew J,Scolyer Richard A,Menzies Alexander M

Funder

GlaxoSmithKline, Novartis, Melanoma Institute Australia

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice;Silva;Curr Opin Oncol,2017

2. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

3. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

4. Improved overall survival in melanoma with combined dabrafenib and trametinib;Robert;N Engl J Med,2015

5. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant therapy for melanoma: past, present, and future;Surgical Oncology;2024-10

2. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma;Hematology/Oncology Clinics of North America;2024-10

3. Therapeutic Treatment Options for In-Transit Metastases from Melanoma;Cancers;2024-09-03

4. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma;Cancer Treatment Reviews;2024-09

5. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma;Annals of Oncology;2024-08